Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Angela Wardman"'
Autor:
Joseph W. Chow, Angela Wardman, David Wilson, Helen Broadhurst, Paul Newell, Katrina Yates, Karen Cheng
Publikováno v:
Drug Safety
Introduction Ceftazidime–avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. Objectives The aim of this study was to evaluate the safety of ceftazidime–av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7039590a66aa6f98c2ba5dd712606bab
http://europepmc.org/articles/PMC7395917
http://europepmc.org/articles/PMC7395917
Autor:
Joseph W. Chow, Gregory G. Stone, Angela Wardman, Jie Song, Helen Broadhurst, Paul Newell, Zhangjing Chen, Leanne B. Gasink, Katrina Yates
Publikováno v:
Journal of Antimicrobial Chemotherapy. 73:2519-2523
Objectives This analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates pooled from the adult Phase III clinical trials in patients with complicated intra-abdominal infectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dc443efc47adc93073dc5a61d43579f
https://doi.org/10.1093/jac/dky204
https://doi.org/10.1093/jac/dky204
Autor:
Greg Stone, Leanne B. Gasink, Angela Wardman, Paul Newell, Peter J. Laud, Jon Armstrong, Yehuda Carmeli
Publikováno v:
The Lancet Infectious Diseases. 16:661-673
Summary Background Carbapenems are frequently the last line of defence in serious infections due to multidrug-resistant Gram-negative bacteria, but their use is threatened by the growing prevalence of carbapenemase-producing pathogens. Ceftazidime-av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54ffc8f37248a44e1f10d741116e7999
https://doi.org/10.1016/s1473-3099(16)30004-4
https://doi.org/10.1016/s1473-3099(16)30004-4
Autor:
Todd Riccobene, Shampa Das, Gregory G. Stone, Wright W. Nichols, Paul Newell, Katrina Yates, Angela Wardman, Helen Broadhurst, Merran MacPherson, Ian A. Critchley
Publikováno v:
Antimicrobial Agents and Chemotherapy
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c918415432eb2821ef2dc48fb2e787
The in vitro activity of ceftazidime-avibactam was evaluated against 341 Gram-negative isolates from 333 patients in a randomized, phase 3 clinical trial of patients with complicated urinary tract or intra-abdominal infections caused by ceftazidime-n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb7d4d2cdb4fd209dc1a7811c1f0ab70
https://europepmc.org/articles/PMC5278708/
https://europepmc.org/articles/PMC5278708/